Event Title

Investigating the effectiveness of Metarrestin as a perinucleolar compartment inhibitor to suppress metastasis

Session Number

Project ID: MEDH 07

Advisor(s)

Dr. Sui Huang, Northwestern University Feinberg School of Medicine

Discipline

Medical and Health Sciences

Start Date

20-4-2022 10:05 AM

End Date

20-4-2022 10:20 AM

Abstract

Cancer is a leading cause of death worldwide and the second leading cause of death in the United States, and the primary cause of mortality is metastasis to other organs. The perinucleolar compartment (PNC) is a sub-nucleolar structure that has been associated with metastasis and the progression of cancer, resulting in poor patient outcomes. To combat metastatic cancer, look towards the drug metarrestin. Metarrestin disrupts the nucleolar structure by inhibiting these perinucleolar compartments, and could potentially be a therapeutic treatment of metastatic cancer. Continuing previous research on the effectiveness of metarrestin as a drug to suppress metastasis, we analyzed the effectiveness of derivatives of metarrestin in inhibiting PNCs by tagging PNCs with antibodies using immunofluorescence. Additionally, looking at soft agar compounds, we have been able to mimic tissue cells and how metarrestin treatment affects tumor cell growth.

Share

COinS
 
Apr 20th, 10:05 AM Apr 20th, 10:20 AM

Investigating the effectiveness of Metarrestin as a perinucleolar compartment inhibitor to suppress metastasis

Cancer is a leading cause of death worldwide and the second leading cause of death in the United States, and the primary cause of mortality is metastasis to other organs. The perinucleolar compartment (PNC) is a sub-nucleolar structure that has been associated with metastasis and the progression of cancer, resulting in poor patient outcomes. To combat metastatic cancer, look towards the drug metarrestin. Metarrestin disrupts the nucleolar structure by inhibiting these perinucleolar compartments, and could potentially be a therapeutic treatment of metastatic cancer. Continuing previous research on the effectiveness of metarrestin as a drug to suppress metastasis, we analyzed the effectiveness of derivatives of metarrestin in inhibiting PNCs by tagging PNCs with antibodies using immunofluorescence. Additionally, looking at soft agar compounds, we have been able to mimic tissue cells and how metarrestin treatment affects tumor cell growth.